Genetic engineering of the bioproduction,
immunogen optimization
Enhanced therapeutic efficacy of GH-pAb validated pharmaceutical development, stability for more than 3 years
Translational development program experience with 3 products in clinic.
Oncology
Immunology
Infectius (virus, bacteria)
Others
Odile
Duvaux
Françoise
Shneiker
Gaëtane
Rouvray
Chief production Officer, Pharm.D, full experience in pharmaceutical production (Sanofi, EFS)
Edwige
Mével
Regulatory Affairs, Pharm D, full experience in several pharma (Innate Pharma, Merck, Sanofi)
A clinical stage Biotech
XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in several indications. Our patented technological platform is built on our expertise in immunology and therapeutics. We develop innovative approaches in immunotherapy with our platform of Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are addressing major therapeutic needs in various domains, including oncology, immunosuppression, viral and bacterial infections. XENOTHERA’s platform allows short-time development thanks to our validated saled-up GMP platform, our in-house bioproduction facility, our clinical experience (400 patients have received GH-pAb today), our mastery of antigens and our regulatory experience. Within less than 8 years, XENOTHERA has brought to clinic LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market, XAB05, a preventive anti- multidrug resistant bacteria GH-pAb, XAV19 an anti-COVID antibody dedicated to patients with moderate disease. XENOTHERA has accumulated preclinical evidence for the therapeutic effect of its oncology GH-pAbs. Two products will be in clinic in oncology in 2023, XON7, its lead pan-cancer targeting solid tumors and LIS22 in peripheral T-Cell lymploma.
POC in Vivo
(PTCL)Toxicology completion
XON7
EMA Scientific Advice
(SOT)LIS1
EMA ODD (SOT)
Phase I/II
CompletionPhase I
CompletionXAB05
Series B
Phase I CTA
XAB05
Phase II
Phase II/IIIPhase I/II
XAB05 & XON POC in vivoPreclinical package
Series ASeed funding
Proof of concept
LIS1
Company creation
Pipeline
Products in development

Latest
News
[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.
December 19, 2022. # Download our press alert (english version) # Télécharger...
More[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.
December 16,2022. # Download our press release (english version) # Télécharger notre...
More[Newsletter] XENONEWS
November 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...
MoreRelated
scientific papers
XENOTHERA is a start-up in biotechnology, developing innovative immunological treatments, specialized in oncology, and other therapeutic domains.
Investors already trusted us since creation by funding the company more than 46M€. Our products are expected to address unsolved major public health issues.
Our vision is to bring new approaches to the patients, as
INNOVATIVE LAB FOR RESPONSIVE CARE .
To contact us, use the form or see our full contact below:
XENOTHERA
21 rue La Nouë Bras de Fer – 44200 Nantes – France
To work with us: careers@xenothera.com
Press Contact: IZsoGOOD – Ingrid Zémor – xenothera@izsogood.co